Now in its fifth edition, this best-selling, multidisciplinary textbook continues to draw on the skills of pharmacists and clinicians to present optimal drug regimens. The authors integrate an understanding of the disease processes with an appreciation of pathophysiological processes, clinical pharmacy and the evidence base.
The incidence of cardiovascular disease has decreased in the last several years with
a better understanding of the pathophysiology of acute coronary syndromes (ACS),
widespread implementation of lipid lowering drugs, improved surgical treatments such
as stent placements, and new therapeutic regimens such as the statins, low molecular
weight heparins, and platelet glycoprotein IIb/IIIa receptor inhibitors. Nevertheless, it
remains today as the leading cause of morbidity and mortality in the Western world....
Although the fifth edition of this book has seen many author changes, our commitment
and direction was clearly stated by, Dr. Helen Cox, in the preface to the fourth edition. We
continue our commitment to providing a nursing focus to the process of nursing care.
The fifth edition reflects seventeen new and six revised diagnoses accepted by
NANDA in 2003 and 2005 and updated information in each chapter. The chapter formats
remain the same. We have revised the integration of NANDA, NIC, and NOC terminology
to assist with understanding their integration.
Nursing in Today’s World: Trends, Issues, and Management, 10th edition focuses on
the nonclinical aspects of the professional nursing role. Much of this content is just as critical
to practicing safely as is competence in the performance of clinical skills. As nursing steps up
to play a major role in the changes brought about by healthcare reform, knowledge of the profession
and its place in the healthcare environment has never been more important.
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; 5-HT, 5hydroxytryptamine.
In general, an adequate dose of whichever agent is chosen should be used as soon as possible after the onset of an attack. If additional medication is required within 60 min because symptoms return or have not abated, the initial dose should be increased for subsequent attacks. Migraine therapy must be individualized; a standard approach for all patients is not possible.
Cancer cells develop strong anti-apoptotic signaling pathways
and therefore escape many therapeutic regimens. Recognizing this
feature of cancer cells, we have focused on two approaches: dis-arming the cancer cell from its anti-apoptotic weaponry [1, 2]
and applying strategies aimed at enhancing pro-apoptotic signa-ling pathways selectively in the cancer cell . The first goal has
been achieved by developing highly selective Aktstatins [1, 2] that
inhibit PKB 100 times better than PKA or PKC.